Mechanisms of action of glatiramer acetate in multiple sclerosis

Neurology

Volumn 56, Issue 6, 2001, Pages 702-708

  Neuhaus, Oliver ^a   Farina, Cinthia ^a   Wekerle, Hartmut ^a   Hohlfeld, Reinhard ^a,b,c  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYELIN BASIC PROTEIN; T LYMPHOCYTE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; DRUG ACTIVATION; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH2 CELL;

EID: 0035957307     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.56.6.702     Document Type: Review

References (86)

1. Copolymer 1: A most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability
2. Progress in determining the causes and treatment of multiple sclerosis
3. Glatiramer acetate or interferon-β for multiple sclerosis? A guide to drug choice
4. Glatiramer acetate
5. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis
6. The development of Cop-1 (Copaxone®), an innovative drug for the treatment of multiple sclerosis: Personal reflections
7. Cop 1 as a candidate drug for multiple sclerosis
8. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
9. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen
10. Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer
11. Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE)
12. Copolymer I inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses
13. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease
14. A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo
15. Copolymer 1 inhibits experimental autoimmune uveoretinitis
16. Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones
17. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1
18. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis
19. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis
20. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Results of a phase III multicenter, double-blind, placebo-controlled trial
21. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
22. The effect of glatiramer acetate (Copaxone®) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): A multi-center, randomized, double blind, placebo-controlled study extended by open-label treatment
23. Effect of copolymer-1 on serial gadolinium enhanced MRI in relapsing remitting multiple sclerosis
24. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS. Quantitative MR assessment
25. Probing into the realm of proteins and immunity
26. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis
27. Specific inhibition of the T cell response to myelin basic protein by the synthetic copolymer Cop-1
28. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein
29. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells - Specificity and promiscuity
30. Studies on the mechanism and specificity of the synthetic copolymer GLAT on graft-versus-host disease
31. Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids
32. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking
33. T suppressor hybridomas and interleukin-2 dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis
34. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis
35. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1
36. Unresponsiveness to experimental allergic encephalomyelitis in mice: Replacement of suppressor cells by a soluble factor
37. Specific TH2 cells are present in the central nervous system of mice protected against EAE by copolymer 1
38. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: Possible therapy for optic neuropathies
39. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: A neuroprotective role of inflammation?
40. Immunogenic potentials of copolymer 1 in normal human lymphocytes
41. Human cellular immune response to copolymer 1 and myelin basic protein
42. Characterization of T cell lines derived from glatiramer-acetate treated multiple sclerosis patients
43. Multiple sclerosis: Comparison of copolymer-1 reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
44. Mechanisms of immunomodulation by glatiramer acetate
45. The lymphocyte proliferative response to glatiramer acetate in normal humans is dependent on both major histocompatibility complex (MHC)
46. Immunological parameters in a multicenter clinical trial of COP1 in multiple sclerosis (MS): A 2-year follow-up
47. Effect of treatment of patients with glatiramer acetate (copolymer-1) on the proliferative response of peripheral blood mononuclear cells to glatiramer acetate in vitro
48. Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
49. Treatment of multiple sclerosis with copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-γ response in blood cells
50. Subcutaneous administration of glatiramer acetate induces antigen specific CD4 T cell tolerance
51. Lymphocyte responses and cytokines
52. The expanding universe of T-cell subsets: Th1, Th2 and more
53. Th1-Th2: Reliable paradigm or dangerous dogma?
54. Helper T cell differentiation
55. Treatment of multiple sclerosis with copolymer-1 (Copaxone®): Implicating mechanisms of Th1 to Th2/Th3 immune deviation
56. Glatiramer acetate (Copolymer-1)-specific, human T cell lines: Cytokine profile and suppression of T cell lines reactive against myelin basic protein (MBP)
57. Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy
58. In vitro glatiramer acetate treatment of brain endothelium does not reduce adhesion phenomena
59. Copolymer-1-induced inhibition of antigen-specific T cell activation: Interference with antigen presentation
60. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules
61. Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules
62. Glatiramer acetate blocks the activation of THP-1 cells by interferon-γ
63. Copolymer-1
64. Cellular immune reactivity within the CNS
65. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex
66. Clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors
67. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
68. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives
69. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein
70. Molecular mimicry and multiple sclerosis: Degenerate T-cell recognition and the induction of autoimmunity
71. Interferons and multiple sclerosis
72. The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis
73. Interferon beta in the treatment of multiple sclerosis. Mechanisms of action
74. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T cells
75. Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific T-helper type 1 lymphocytes
76. Down-regulation of interferon-γ-induced class II expression on human glioma cells by recombinant interferon-β: Effects of dosage treatment schedule
77. Interferon (IFN) β acts downstream of IFN-γ-induced class II transactivator messenger RNA accumulation to block histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-γ
78. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis
79. Interferon beta-1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9
80. Changes of serum sICAM-1 and MMP-9 induced by rINFβ-1b treatment in relapsing-remitting MS
81. Immunomodulatory effects of interferon-β-1b in vivo: Induction of the expression of transforming growth factor-β1 and its receptor type II
82. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon-beta
83. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis
84. Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patients
85. IFN-β-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: Relevance to IFN-β-1b therapeutic effects in multiple sclerosis
86. Antagonistic action of IFN-β and IFN-γ on high affinity Fcγ receptor expression in healthy controls and multiple sclerosis patients